Journal
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
Volume 16, Issue 11, Pages 1109-1124Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/17425255.2020.1815705
Keywords
Drug metabolizing enzymes; chemotherapy; reactive metabolites; gastrointestinal toxicity; hepatotoxicity
Funding
- NIH [R01HL129794, 1R01ES029382, 1P42 ES0327725]
- Cancer Prevention Research Institute of Texas (CPRIT) [RP190279]
Ask authors/readers for more resources
Introduction Toxicity of chemotherapy drugs is the leading cause of poor therapeutic outcome in many cancer patients. Gastrointestinal (GI) toxicity and hepatotoxicity are among the most common side effects of current chemotherapies. Emerging studies indicate that many chemotherapy-induced toxicities are driven by drug metabolism, but very few reviews summarize the role of drug metabolism in chemotherapy-induced GI toxicity and hepatotoxicity. In this review, we highlighted the importance of drug metabolizing enzymes (DMEs) in chemotherapy toxicity. Areas covered Our review demonstrated that altered activity of DMEs play important role in chemotherapy-induced GI toxicity and hepatotoxicity. Besides direct changes in catalytic activities, the transcription of DMEs is also affected by inflammation, cell-signaling pathways, and/or by drugs in cancer patients due to the disease etiology. Expert opinion More studies should focus on how DMEs are altered during chemotherapy treatment, and how such changes affect the metabolism of chemotherapy drug itself. This mutual interaction between chemotherapies and DMEs can lead to excessive exposure of parent drug or toxic metabolites which ultimately cause GI adverse effect.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available